c
cc  


 
c c    c
cc  
 
  c 
c
  c
 c 
Acute and Absorption: Alters Contraindicated in: CNS: seizures, 1.p Assess mental
chronic Well absorbed following the hypersensitivity, CNS extrapyramidal status prior to and
psychotic PO/IM administration effects of depression, severe liver reactions, periodically during
disorders Distribution: dopamin or cardiovascular confusion, therapy.
including
Concentrates in liver e in the disease. drowsiness, 2.p Assess positive and
schizophrenia,
Protein Binding: 90% CNS. restlessness, negative
manic states,
drug-induced Diminish Use cautiously in tardive dyskinesia symptoms of
psychoses ed signs debilitated patients, EENT: blurred schizophrenia.
and cardiac disease, vision, dry eyes 3.p Observe patient
sympto diabetes, respiratory Resp: respiratory carefully when
ms of insufficiency, seizures depression administering
psychose CV: hypotension, medication, to
s tachycardia ensure that
GI: constipation, medication is
dry mouth, actually taken and
anorexia, weight not hoarded.
gain 4.p Monitor patient
GU: urinary for onset of
retention akathisia which
Derm: diaphoresis, may appear within
rashes 6hr of 1st dose and
may be difficult to
distinguish from
psychotic agitation
5.p Monitor tardive
dyskinesia. Report
immediately; may
be irreversible
6.p Monitor for
development of
 neuroleptic
malignant
syndrome
7.p Instruct patient of
use frequent
mouth rinses,
good oral hygiene,
and sugarless gum
or candy to
minimize dry
mouth.
8.p Advise patient to
change positions
slowly to minimize
orthostatic
hypotension
Drug: mefanamic acid

c
cc 

 
c c    c
cc 
 
c
  c 
     c
 c

Relief of pain Absorption: well Aspirin like- ëp Nausea and ëp Assess
Distribution: wide drug that has vomiting, patients for
Metabolism: liver analgesic, drowsiness, pain before
Excretion: kidney (50%), antipyretic & dizziness therapy:
liver (20%) ant- location,
inflammatory ëp Gastrointestinal duration,
Half life: 2-4 hours activities. discomfort, precipitating
These diarrhea or and
activities constipation, gas alleviating
appear to be pain, nervousness, factors.
its ability to visual
inhibit disturbances, ëp Assess/
cyclooxygenas autoimmune monitor
e and also hemolytic possible
antagonize anaemia, drug
certain effects bronchoconstrictio induced
of n adverse
prostaglandins reactions
.
ëp Assess
patient͛s
knowledge
or drug
therapy
Drug: biperiden

c
cc  

 
c c    c
cc  
 
  c 
c
  c
 c 
Parkinsonian Absorption: well absorbed Synthetic ëp drowsiness, Document indication
syndrome Distribution: unknown anticholinergic dizziness, for therapy, onset of
especially to Metabolism: unknown drug, blocks fatigue and signs and
counteract Excretion: unknown cholinergic blurring of symptomsnd other
muscular responses in vision, dry agents tried &
rigidity and Half life:18 -24 hours the CNS mouth outcome of therapy
tremor;
ëp ataxia, anxiety, Monitor input and
extrapyramidal
symptoms confusion output ratio

Assess for shuffling

gait, involuntary
movements and
muscle spasms

Emphasize that doses

should not be
doubled but missed
dose may be taken
up to 2 hours before
next dose

Avoid activities that

require alertness
Caution patient to
rise slowly from
sitting or recumbent
positions to minimize
orthostatic
hypotension
Drug: ascorbic acid (vitamin C)

c
cc 

 
c c    c
cc  
   c 

c
  c
 c 

Enhance body͛s Absorption: readily (PO) Needed for polyurea Assess if patient has
natural immune Distribution: wide wound healing, difficulty in
function Metabolism: oxidation collagen swallowing
Excretion: kidneys synthesis,
antioxidant, CHO Assess nutritional
Half life: unknown metabolism, status for inclusion of
protein, lipid foods high in vitamin
synthesis, C
prevention of Teach patient not to
infection chew capsules/
tablets